These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23121392)

  • 1. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
    Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
    Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.
    Yan C; Yang M; Li Z; Li S; Hu X; Fan D; Zhang Y; Wang J; Xiong D
    Biomaterials; 2014 Mar; 35(9):3035-43. PubMed ID: 24406219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy in B-NHL cell line using adenovirus-mediated transfer of secretable trimeric TRAIL gene expression driven by CD20 promoter.
    Yuan XF; Peng HW; Ding YH; Yan CH; Zhang YJ; Yang M; Xiong DS
    Exp Hematol; 2013 Mar; 41(3):221-30. PubMed ID: 23142221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects.
    Yan C; Song X; Yu W; Wei F; Li H; Lv M; Zhang X; Ren X
    Tumour Biol; 2016 Jun; 37(6):8425-35. PubMed ID: 26733169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
    Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
    Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
    Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
    Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
    Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
    Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
    Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
    Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection.
    Hu YL; Huang B; Zhang TY; Miao PH; Tang GP; Tabata Y; Gao JQ
    Mol Pharm; 2012 Sep; 9(9):2698-709. PubMed ID: 22862421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
    Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
    J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
    Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
    Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
    J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
    Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
    J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
    Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
    Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
    Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
    J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.